Trustworthy development and commercial manufacturing of CELL&GENE therapies.
-
On december 1st 2023, Seqens completed the acquisition of CELLforCURE
-
Originally a versatile CELL&GENE CDMO, CELLforCURE gained thorough experience in commercial CAR-T cells manufacturing
-
CELLforCURE teams aim at partnering with innovators to develop and manufacture CELL&GENE therapies for today and tomorrow
Capabilities
01
Site Facility
With 2 200m2 GMP production areas, 6 equipped production suites and 180 seasoned highly skilled experts, CELLforCURE offers versatile and flexible capacities CELLforCURE is located in France, 20km away from the Paris Orly Airport.
02
Technologies & Equipment
CELLforCURE is an EMA approved production site and is compliant with FDA standards. The site brings analytical, development and regulatory services to serve client needs across the overall product life cycle.
Key Figures
2
Autologous batches / day validated capacity
10 years
of Experience in CELL&GENE therapy
2200m2
GMP classified production area
Corporate Social Responsibility can be defined as the integration by companies of social and environmental concerns in their activities and their relations with stakeholders.
As a global player in pharmaceutical solutions and specialty ingredients, SEQENS is committed to making corporate social responsibility a priority.
